
|Articles|September 10, 2015
Certara, Paidion Research Form Pediatric Drug Partnership
Certara® and Paidion Research, announced a new partnership to address the challenges inherent in pediatric drug development.
Advertisement
Certara®, a global biosimulation technology-enabled drug development company, and Paidion Research, a pediatric clinical research organization (CRO), announced a new partnership to address the challenges inherent in pediatric drug development including safe and effective dose or dose ranges and the conduct of trials. The partnership joins together Certara’s Simcyp® Pediatric PBPK simulator to inform the dose selections, with Paidon’s neonatal and pediatric intensive care unit and pediatric clinical site networks and clinical trials experience.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
2
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
3
Breaking the Efficacy Ceiling in IBD and Beyond
4
ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma
5




